SEC Form 4 · accession 0001209191-18-003958
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Jan 16, 2018
Accepted (ET)
Jan 17, 2018 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 16, 2018 | M | 1,719 | $96.87 | A | 56,143 | D | |
| Common StockF2,F3 | Jan 16, 2018 | S | 519 | $155.80 | D | 55,624 | D | |
| Common StockF3,F4 | Jan 16, 2018 | S | 900 | $157.54 | D | 54,724 | D | |
| Common Stock | Jan 16, 2018 | S | 300 | $159.04 | D | 54,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $96.87 | Jan 16, 2018 | M | 1,719 | D | — | Jul 14, 2024 | Common Stock | 1,719 | 3,438 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $155.80 (range $155.77 to $155.91).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $157.54 (range $156.95 to $157.83).
- F5The option vests in 16 quarterly installments from 7/15/2014.